| 李莹,陆昭雪,张旭光.程序性死亡配体 1抑制剂联合抗血管生成药物治疗非肝炎病毒相关性原发性肝细胞癌的疗效和安全性分析[J].安徽医药,2026,30(5):1049-1053. |
| 程序性死亡配体 1抑制剂联合抗血管生成药物治疗非肝炎病毒相关性原发性肝细胞癌的疗效和安全性分析 |
| Efficacy and safety of PD-L1 inhibitors combined with anti-angiogenic drugs in the treatment of advanced non-HBV non-HCV -related hepatocellular carcinoma |
| |
| DOI：10.3969/j.issn.1009-6469.2026.05.041 |
| 中文关键词: 肝肿瘤 程序性死亡配体 1 靶向治疗 免疫治疗 临床疗效 安全性 |
| 英文关键词: Liver neoplasms Programmed death-ligand 1 Targeted therapy Immunotherapy Clinical efficacy Safety |
| 基金项目: |
|
| 摘要点击次数: 244 |
| 全文下载次数: 68 |
| 中文摘要: |
| 目的分析乙型肝炎(乙肝)病毒相关性原发性肝细胞癌( HCC)和非肝炎病毒相关性 HCC使用程序性死亡受体 1/程序性死亡配体 1(PD-1/PD-L1)抑制剂联合抗血管生成药物治疗的疗效和安全性差异。方法选取 2020年 2月至 2023年 2月于徐州市肿瘤医院就诊的使用 PD-1/PD-L1抑制剂联合抗血管生成药物治疗的中晚期 HCC病人 60例，根据是否合并乙肝将病人分为非乙肝组和乙肝组。分析两组病人近期疾病缓解率( ORR)、疾病控制率( DCR)、无进展生存时间( PFS)、总生存时间( OS)和不良反应发生情况有无差异。结果非乙肝组 ORR、DCR为 21.4%、50.0%，明显低于乙肝组 46.9%、75.0%，差异有统计学意(P<0.05)；非乙肝组中位 PFS和中位 OS分别为 7.3个月和 13.0个月，低于乙肝组 8.8个月和 16.7个月，差异有统计学意义( P<0.0义5)。两组病人最常见的不良反应均为胃肠道反应和继发性高血压，予对症治疗后均可好转，差异无统计学意义( P>0.05)。结论非肝炎病毒相关性 HCC可能对 PD-1/PD-L1联合抗血管生成药物联合治疗较不敏感，总体疗效低于乙肝病毒相关性 HCC，但安全性可控，毒副作用可耐受。 |
| 英文摘要: |
| Objective To analyze the difference in efficacy and safety between hepatitis B virus-associated hepatocellular carcinoma and non-virus-associated hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors in combination with anti-angiogenic drugs. Methods Sixty patients with intermediate and advanced primary hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors com. bined with anti-angiogenic drugs who were hospitalized in Xuzhou Cancer Hospital from February 2020 to February 2023 were select.ed, and the patients were categorized into non-hepatitis B and hepatitis B groups based on the presence or absence of hepatitis B comor. bidity. The patients were treated with PD-1/PD-L1 inhibitors in combination with anti-angiogenic drugs. We analyzed whether therewas any difference in the recent disease remission rate (ORR), disease control rate (DCR), progression-free survival time (PFS), overall survival time (OS) and the occurrence of adverse reactions between the two groups.Results The ORR and DCR of the non-hepatitis B group were 21.4% and 50.0%, which were significantly lower than those of the hepatitis B group, 46.9% and 75.0%, and the difference was statistically significant (P<0.05). The median PFS and median OS in the non-hepatitis B group were 7.3 months and 13.0 months,respectively, which were lower than those in the hepatitis B group of 8.8 months and 16.7 months, and the difference was statisticallysignificant (P<0.05). The most common adverse reactions in both groups were gastrointestinal reactions and secondary hypertension,which could be improved after symptomatic treatment, and the difference was not statistically significant (P>0.05). Conclusion NBNC-HCC may be less sensitive to PD-1/PD-L1 combined with anti-angiogenic drugs combination therapy, and the overall efficacy is lower than that of hepatitis B virus-associated HCC, but the safety is manageable and the toxicities are tolerable. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
